Highlights: IHL-42X reduced primary endpoint apnoea hypopnea index relative to baseline at all three doses that were assessed Low dose IHL-42X exhibited superior safety and efficacy metrics to mid and high doses Low dose IHL-42X reduced AHI by an average of 50.7% compared to baseline with 25% of participants experiencing a reduction in the apnoea hypopnea index of greater that 80%


Previous articlePT330 – Dick Simon – Researching Ethnobotanical Efficacy and the Search For New Therapeutic Molecules
Next articleRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19